In November 2021, news broke that Sweden-based modular prefabricated facility solutions provider, KeyPlants, had been acquired by Masco Group. The company has been steadily gaining traction in recent years with some high-profile projects, such as an African COVID-19 vaccine collaboration in August of 2021. As a key part of this growth, Head of Sales, David Lindholm has seen it all.Lindholm came to KeyPlants in 2019 with an expansive history of 20 years in engineering and the pharmaceutical industry. Gaining his Masters in Chemical Engineering, Lindholm worked his way up to a managerial role at CDMO Recipharm growing from a local company to an international one. He then moved to life sciences expert Patheon, seeing the company through its 2017 acquisition by Thermo Fisher Scientific as Director of Business Development Europe.By all accounts, Lindholm is now well practiced at managing change and transition periods.The sales expert explains that moving from operations into business development early on was a crucial time in his career.It is in these years that Lindholm gained an appreciation for what the pharmaceutical industry needed, and how the design build sector could facilitate this. "Pharmaceutical companies and CDMOs were all lacking capacity for biomanufacturing and fill-finish," he explains. "Challenges related to manufacturing slot reservation being one example. Another example would be long time schedules in capital projects."Lindholm explains that his move to KeyPlants was in part motivated by the company's mission to simplify and shorten the lead time for building biologics production capacity. "This was exactly what the market was looking for," he says. He also mentions that the opportunity to develop and help shape how KeyPlants manage accounts, their business development and marketing was something he was attracted to.
展开▼
